Touchlight Genetics Ltd is a British biotechnology company operating in the field of DNA therapies and DNA technology. Touchlight’s proTL™ process is capable of large-scale enzymatic manufacture of doggybone™ closed linear DNA (dbDNA™). The DNA produced is distinctive in its structure and manufactured without the requirement for bacterial fermentation.
Touchlight was established in 2008 on the conviction that our ever-increasing understanding of DNA would lead to its emergence as a material of the future.
Since its founding, they’ve developed, patented, scaled and evidenced a revolutionary platform to enable the next generation of genetic medicines and DNA industries.
Touchlight is situated at the Morelands and Riverdale Buildings in Hampton, UK. These state-of-the-art facilities have been established in a restored Victorian water works on the River Thames.
|Aim of funding||Growth|
|HMRC Advanced Assurance received||Yes|
|Envisaged investor exit||4-5 years|
|Targeted return||In excess of 4x capital invested|